Psammoma Bodies in Lung Adenocarcinoma: Incidence and Association With ALK/ROS1/RET Fusions

被引：0
|
作者：
Li, Yuan
Shen, Xuxia
Wang, Rui
Hu, Haichuan
Chen, Haiquan
Mukhopadhyay, Sanjay
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[2] Cleveland Clin, Cleveland, OH 44106 USA
来源：
MODERN PATHOLOGY | 2015年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1937
引用
收藏
页码：483A / 483A
页数：1
相关论文
共 50 条
  • [41] Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Arrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients
    Song, Zhengbo
    Yu, Xinmin
    Zhang, Yiping
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S494 - S494
  • [42] Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples
    Zhao, Chao
    Li, Xuefei
    Li, Jiayu
    Zhang, Yishi
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhou, Caicun
    TRANSLATIONAL ONCOLOGY, 2014, 7 (03): : 363 - 367
  • [43] Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients
    Song, Zhengbo
    Yu, Xinmin
    Zhang, Yiping
    CANCER BIOLOGY & THERAPY, 2017, 18 (11) : 883 - 887
  • [44] Cognitive Impact of Lorlatinib Administration in Advanced Non Small Cell Lung Cancer with ALK and ROS1 Fusions
    Tanzilli, A.
    Tosetto, L.
    Landi, L.
    Villani, V.
    Di Noia, V.
    Fusco, F.
    Pace, A.
    Stati, V.
    Cappuzzo, F.
    Cecere, F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S641 - S641
  • [45] ALK, ROS1, RET and NTRK1-3 Gene Fusions in Colorectal and Non-Colorectal Microsatellite-Unstable Cancers
    Mulkidjan, Rimma S.
    Saitova, Evgeniya S.
    Preobrazhenskaya, Elena V.
    Asadulaeva, Karimat A.
    Bubnov, Mikhail G.
    Otradnova, Ekaterina A.
    Terina, Darya M.
    Shulga, Sofia S.
    Martynenko, Darya E.
    Semina, Maria V.
    Belogubova, Evgeniya V.
    Tiurin, Vladislav I.
    Amankwah, Priscilla S.
    Martianov, Aleksandr S.
    Imyanitov, Evgeny N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [46] The landscape of clinically actionable ALK/MET/RET/ROS1 fusions to reveal a shared pattern of protein domains in fusion partners.
    Ritterhouse, Lauren
    Dias-Santagata, Dora
    Nardi, Valentina
    Iafrate, A. John
    Le, Long P.
    Lennerz, Jochen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] ROS1 Immunohistochemistry as a Screen for ROS1 Rearrangements in Lung Adenocarcinoma: Application in Clinical Practice
    Pal, Prodipto
    Hammerman, Peter
    Kwiatkowski, David J.
    Johnson, Bruce E.
    Sholl, Lynette M.
    MODERN PATHOLOGY, 2016, 29 : 478A - 478A
  • [48] ROS1 Immunohistochemistry as a Screen for ROS1 Rearrangements in Lung Adenocarcinoma: Application in Clinical Practice
    Pal, Prodipto
    Hammerman, Peter
    Kwiatkowski, David J.
    Johnson, Bruce E.
    Sholl, Lynette M.
    LABORATORY INVESTIGATION, 2016, 96 : 478A - 478A
  • [49] Comprehensive analysis of ALK, ROS1 and RET rearrangements in locally advanced rectal cancer
    Chunlian Zhou
    Min Li
    Zhiwei Guo
    Kun Li
    Xiangming Zhai
    Yingchao Xie
    Xuexi Yang
    Yingsong Wu
    Weiwei Xiao
    Weiwen Xu
    Journal of Genetics, 2020, 99
  • [50] Novel targeted therapy beyond EGFR and ALK: ROS1, BRAF, RET and MET
    Yoh, Kiyotaka
    ANNALS OF ONCOLOGY, 2019, 30
12345